May 9, 2023

Ascidian Therapeutics to Present New Data From Its Lead Program Targeting ABCA4 Retinopathies at the ASGCT 2023 Annual Meeting

April 18, 2023

Ascidian Therapeutics to Present Data From Its Lead Program Targeting ABCA4 Retinopathies at the Retinal Cell and Gene Therapy Innovation Summit and ARVO 2023 Annual Meeting

April 11, 2023

Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic

March 20, 2023

Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer

January 4, 2023

Ascidian Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

October 12, 2022

Ascidian Therapeutics Launches to Rewrite RNA